The FDA says Eli Lillys cancer drug Lartruvo shouldnt be started in new patients following a key study that failed to show the medicine prolonged lives httpsbloom.bg2DwNLG5Â
The FDA says Eli Lilly’s cancer drug Lartruvo shouldn’t be started in new patients, following a key study that failed to show the medicine prolonged lives https://bloom.bg/2DwNLG5
More From BioPortfolio on "The FDA says Eli Lilly’s cancer drug Lartruvo shouldn’t be started in new patients, following a key study that failed to show the medicine prolonged lives https://bloom.bg/2DwNLG5 "